Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis

  1. Alexander Tsertsvadze, MD, MSc;
  2. Howard A. Fink, MD, MPH;
  3. Fatemeh Yazdi, MSc;
  4. Roderick MacDonald, MSc;
  5. Anthony J. Bella, MD;
  6. Mohammed T. Ansari, MBBS, MMedSc, MPhil;
  7. Chantelle Garritty, MSc;
  8. Karla Soares-Weiser, MD, PhD;
  9. Raymond Daniel, BA;
  10. Margaret Sampson, MLIS;
  11. Steven Fox, MD, MPH;
  12. David Moher, PhD; and
  13. Timothy J. Wilt, MD, MPH
  1. From Ottawa Health Research Institute, University of Ottawa, and Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada; Geriatric Research Education and Clinical Center, Center for Chronic Disease Outcomes Research, Minneapolis Veterans Affairs Medical Center, and Minneapolis Evidence-based Practice Center, Minneapolis, Minnesota; Enhance Reviews, Kfar-Saba, Israel; and Agency for Healthcare Research and Quality, Rockville, Maryland.
    1. Appendix Figure 1.
      View larger version:
        Appendix Figure 1. Literature search and selection.

        NAION = nonarteritic anterior ischemic optic neuropathy.

      • Appendix Figure 2.
        View larger version:
          Appendix Figure 2. Improvement in erections: sildenafil versus placebo.

          CAD = coronary artery disease; CVD = cardiovascular disease; RR = relative risk.

        • Appendix Figure 3.
          View larger version:
            Appendix Figure 3. Improvement in erections: vardenafil versus placebo.

            RR = relative risk.

          • Appendix Figure 4.
            View larger version:
              Appendix Figure 4. Improvement in erections: tadalafil versus placebo.

              RR = relative risk.

            Summary for Patients

            « Previous | Next Article »Table of Contents